Patent Application
20230390247
The present disclosure relates to a pharmaceutical composition containing biphenylpyrrolidine and biphenyldihydroimidazole derivatives for inhibiting the activity of the 5-HT7 serotonin receptor as an active ingredient, more particularly to a pharmaceutical composition containing biphenylpyrrolidine and biphenyldihydroimidazole derivatives, which are capable of inhibiting the activity of the serotonin receptor by acting as an antagonist in the P-arrestin signaling pathway, as an active ingredient.
The neurotransmitter serotonin triggers various physiological processes by acting on 14 different serotonin receptors distributed in various organs. Each receptor induces various physiological responses through interaction with serotonin. Among them, the 5-HT7 receptor, which is the most recently found serotonin subtype receptor, is distributed a lot especially in the hypothalamus, thalamus, hippocampus, cortex, etc. and is known to play important roles such as body temperature regulation, biorhythms, learning and memory, sleep, hippocampal signaling, etc. In addition, it is known to be involved in neurological disorders such as depression, migraine, anxiety, developmental disorder, inflammatory pain, neuropathic pain, etc.
With the progress of researches on GPCRs, it has been known that there are signaling systems dependent on the activity of G protein and β-arrestin and the activity of the two signaling systems can be regulated depending on the structure of GPCR ligands. Therefore, various ligands are being developed. The 5-HT7 receptor is one of GPCRs (G protein-coupled receptors) and an assay system capable of identifying the presence and activity of the G protein signaling system and the β-arrestin signaling system have been developed (Journal of Medicinal Chemistry, 2018, 61, 7218). It is known that SB-269970, which is well known as a 5-HT7 receptor antagonist, acts as an antagonist against the G protein and β-arrestin signaling systems.
However, it is necessary to develop various β-arrestin antagonists because researches on the activity of β-arrestin are insufficient.
(Patent document 1) Korean Patent Registration No. 10-1779991.
The present disclosure is directed to providing a biphenylpyrrolidine/dihydroimidazole derivative, which is capable of inhibiting the activity of the 5-HT7 serotonin receptor by acting as an antagonist of the p-arrestin pathway for the 5-HT7 serotonin receptor, or a pharmaceutically acceptable salt thereof.
The present disclosure is also directed to providing a pharmaceutical composition for preventing or treating a central nervous system disease such as sleep disorder, depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, thermoregulation disorder, biorhythm disorder, developmental disorder including autism spectrum disorder, smooth muscle disorder, etc., which contains the biphenylpyrrolidine/dihydroimidazole derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
In an aspect, the present disclosure provides a compound for inhibiting the activity of the 5-HT7 serotonin receptor, which is represented by Structural Formula 1 or 2, or a pharmaceutically acceptable salt thereof.
In Structural Formula 1 or 2,
each of R1 to R8, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, the compound represented by Structural Formula 1 or 2 may be represented by Structural Formula 3 or 4.
In Structural Formula 3 or 4,
each of R9 to R16, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, each of R9 to R16, which are identical to or different from each other, may be independently a hydrogen atom, a chloro group, a C1-C4 alkyl group or a C1-C4 alkoxy group.
The compound represented by Structural Formula 1 or 2 may be any one selected from the following compounds 1-44.
The pharmaceutically acceptable salt may be a salt formed using any inorganic acid or organic acid selected from hydrochloric acid, bromic acid, sulfonic acid, amidosulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, tartaric acid, citric acid, p-toluenesulfonic
In another aspect, the present disclosure provides a method for preparing a compound represented by Structural Formula 1 or 2 for inhibiting the activity of the 5-HT7 serotonin receptor, which includes a step of reacting a compound represented by Structural Formula A with pyrrolidine or ethylenediamine.
In Structural Formula 1 or 2,
each of R 1 to R 8 , which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group, and
in Structural Formula A,
each of R17 to R20, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, the compound represented by Structural Formula 1 or 2 may be represented by Structural Formula 3 or 4, and
the compound represented by Structural Formula A may be represented by Structural Formula B.
In Structural Formula 3 or 4,
each of R9 to R16, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group, and
in Structural Formula B,
each of R21 to R24, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
The compound represented by Structural Formula B may be prepared by the Suzuki reaction of a compound represented by Structural Formula C and a compound represented by Structural Formula D.
In Structural Formula C or D,
X1 is a bromo group or an iodo group, and
each of R25 and R26, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, R25 may be a hydrogen atom and X1 may be a bromo group.
Also, specifically, R26 may be a chloro group and X1 may be an iodo group.
In another aspect, the present disclosure provides a pharmaceutical composition for preventing or treating a central nervous system disease, which contains a compound represented by Structural Formula 1 or 2 or a pharmaceutically acceptable salt thereof as an active ingredient.
In Structural Formula 1 or 2,
each of R1 to R8, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Most specifically, the compound represented by Structural Formula 1 or 2 may be any one selected from the following compounds 1-44.
The central nervous system disease may be any disease selected from sleep disorder, depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, thermoregulation disorder, biorhythm disorder, autism spectrum disorder and smooth muscle disorder.
The biphenylpyrrolidine/dihydroimidazole derivative of the present disclosure and a pharmaceutically acceptable salt thereof can inhibit the activity of the 5-HT7 serotonin receptor because it exhibits superior binding affinity and superior antagonistic activity for the 5-HT7 serotonin receptor. Accordingly, a pharmaceutical composition containing the same as an active ingredient is effective in preventing or treating a brain disease including a central nervous system disease, specifically, depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, thermoregulation disorder, biorhythm disorder, sleep disorder, developmental disorder including autism spectrum disorder, smooth muscle-related disease, etc. that requires the inhibition of the activity of the 5-HT7 serotonin receptor.
The present disclosure may be changed variously and may have various exemplary embodiments. Hereinafter, the specific exemplary embodiments of the present disclosure will be described in detail. However, the present disclosure is not limited to specific exemplary embodiments but encompasses all changes, equivalents and substitutes included within the technical idea and scope of the present disclosure. When describing the present disclosure, detailed description of well-known matters may be omitted to avoid unnecessarily obscuring the present disclosure.
The term “substituted” means that at least one hydrogen atom is substituted with a substituent selected from a group consisting of deuterium, a C1-C30 alkyl group, a C3-C30 cycloalkyl group, a C2-C30 heterocycloalkyl group, a C1-C30 haloalkyl group, a C6-C30 aryl group, a C1-C30 heteroaryl group, a C1-C30 alkoxy group, a C3-C30 cycloalkoxy group, a C1-C30 heterocycloalkoxy group, a C2-C30 alkenyl group, a C2-C30 alkynyl group, a C6-C30 aryloxy group, a C1-C30 heteroaryloxy group, a silyloxy group (—OSiH3), —OSiR1H2 (R1 is a C1-C30 alkyl group or a C6-C30 aryl group), —OSiR1R2H (each of R1 and R2 is independently a C1-C30 alkyl group or a C6-C30 aryl group), —OSiR1R2R3 (each of R1, R2 and R3 is independently a C1-C30 alkyl group or a C6-C30 aryl group), a C1-C30 acyl group, a C2-C30 acyloxy group, a C2-C30 heteroaryloxy group, a C1-C30 sulfonyl group, a C1-C30 alkylthio group, a C3-C30 cycloalkylthio group, a C1-C30 heterocycloalkylthio group, a C6-C30 arylthio group, a C1-C30 heteroarylthio group, a C1-C30 phosphoramide group, a silyl group (SiR1R2R3) (each of R1, R2 and R3 is independently a hydrogen atom, a C1-C30 alkyl group or a C6-C30 aryl group), an amine group (—NRR′) (each of R and R′ is independently a substituent selected from a group consisting of a hydrogen atom, a C1-C30 alkyl group and a C6-C30 aryl group), a carboxyl group, a halogen group, a cyano group, a nitro group, an azo group and a hydroxyl group.
In addition, two neighboring substituents may be fused to form a saturated or unsaturated ring.
The number of carbons in the alkyl group or the aryl group of “substituted or unsubstituted C1-C30 alkyl group”, “substituted or unsubstituted C6-C30 aryl group”, etc. means the number of the carbons constituting the alkyl or aryl moiety without considering the substituent. For example, a phenyl group in which a butyl group is substituted at the para-position is a C6 aryl group substituted with a C4 butyl group.
In the present specification, “hydrogen” refers to hydrogen, deuterium or tritium unless defined otherwise.
In the present specification, the term “alkyl group” refers to an aliphatic hydrocarbon group unless defined otherwise.
The alkyl group may be a “saturated alkyl group” containing no double or triple bond.
The alkyl group may also be an “unsaturated alkyl group” containing at least one double or triple bond.
The alkyl group may be branched, straight or cyclic whether it is saturated or unsaturated.
The alkyl group may be a C1-C30 alkyl group. More specifically, it may be a C1-C20 alkyl group, a C1-C10 alkyl group or a C1-C6 alkyl group.
For example, a C1-C4 alkyl group has 1-4 carbon atoms in the alkyl chain. That is to say, the C1-C4 alkyl group may be selected from a group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and t-butyl.
As specific examples, the alkyl group may be a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a t-butyl group, a pentyl group, a hexyl group, an ethenyl group, a propenyl group, a butenyl group, a cyclopropyl group, a cyclobutyl group, a cyclopenyl group, a cyclohexyl group, etc.
In the present specification, the expression ‘containing as an active ingredient’ means that the 2,6-diarylenebenzoxazole derivative or a pharmaceutically acceptable salt thereof is contained in an amount sufficient to achieve the desired efficacy or activity. For example, the 2,6-diarylenebenzoxazole derivative or a pharmaceutically acceptable salt thereof may be used at a concentration of 10-1500 μg/mL, specifically 100-1000 μg/mL. However, the scope of the present disclosure is not limited thereto and the upper limit of the amount of the 2,6-diarylenebenzoxazole derivative contained in the pharmaceutical composition of the present disclosure may be selected adequately by those skilled in the art.
Hereinafter, the compound for inhibiting the activity of the 5-HT7 serotonin receptor or a pharmaceutically acceptable salt thereof of the present disclosure will be described in detail.
The compound for inhibiting the activity of the 5-HT7 serotonin receptor of the present disclosure is represented by Structural Formula 1 or 2.
In Structural Formula 1 or 2,
each of R1 to R8, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, the compound represented by Structural Formula 1 or 2 may be represented by Structural Formula 3 or 4.
In Structural Formula 3 or 4,
each of R9 to R16, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, each of R9 to R16, which are identical to or different from each other, may independently be a hydrogen atom, a chloro group, a C1-C4 alkyl group or a C1-C4 alkoxy group.
Most specifically, the compound represented by Structural Formula 1 or 2 may be any one selected from the following compounds 1-44.
The pharmaceutically acceptable salt may be a salt formed using any inorganic acid or organic acid selected from hydrochloric acid, bromic acid, sulfonic acid, amidosulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, tartaric acid, citric acid, p-toluenesulfonic acid and methanesulfonic acid.
Hereinafter, a method for preparing the compound for inhibiting the activity of the 5-HT7 serotonin receptor or a pharmaceutically acceptable salt thereof according to the present disclosure will be described.
The method for preparing the compound for inhibiting the activity of the 5-HT7 serotonin receptor or a pharmaceutically acceptable salt thereof according to the present disclosure may include a step of reacting a compound represented by Structural Formula A with pyrrolidine or ethylenediamine.
In Structural Formula 1 or 2,
each of R1 to R8, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group, and,
in Structural Formula B,
each of R17 to R20, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, the compound represented by Structural Formula 1 or 2 may be represented by Structural Formula 3 or 4, and the compound represented by Structural Formula A may be represented by Structural Formula B.
In Structural Formula 3 or 4,
each of R9 to R16, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group, and,
in Structural Formula A,
each of R21 to R24, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
The compound represented by Structural Formula B may be prepared by the Suzuki reaction of a compound represented by Structural Formula C with a compound represented by Structural Formula D.
In Structural Formula C or D,
X1 is a bromo group or an iodo group, and
each of R25 and R26, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
Specifically, R25 may be a hydrogen atom and X1 may be a bromo group.
Also, specifically, R26 may be a chloro group and X1 may be an iodo group.
The present disclosure provides a pharmaceutical composition for preventing or treating a central nervous system disease, which contains a compound represented by Structural Formula 1 or 2 or a pharmaceutically acceptable salt thereof as an active ingredient.
In Structural Formula 1 or 2,
each of R1 to R8, which are identical to or different from each other, is independently a hydrogen atom, a halogen group, a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C1-C10 alkoxy group.
The description about the compound represented by Structural Formula 1 or 2 will be omitted because it was described in detail above.
The central nervous system disease may be any disease selected from sleep disorder, depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, thermoregulation disorder, biorhythm disorder, autism spectrum disorder and smooth muscle disorder.
The pharmaceutical composition of the present disclosure may be prepared using a pharmaceutically acceptable and physiologically allowed adjuvant in addition to the active ingredient. The adjuvant may be an excipient, a disintegrant, a sweetener, a binder, a coating agent, a swelling agent, a lubricant, a glidant, a flavorant, etc.
The pharmaceutical composition may be prepared into a formulation using one or more pharmaceutically acceptable carrier in addition to the active ingredient described above.
The pharmaceutical composition may be prepared into a formulation such as a granule, a powder, a tablet, a coated tablet, a capsule, a suppository, a liquid, a syrup, a juice, a suspension, an emulsion, a medicinal drop, an injectable liquid, etc. For example, for formulation into a tablet or a capsule, the active ingredient may be bound to an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, etc. Also, if desired or necessary, a suitable binder, lubricant, disintegrant or coloring agent may be added. The suitable binder includes but is not limited to starch, gelatin, natural sugar such as glucose or β-lactose, corn sweetener, natural or synthetic gum such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. The disintegrant includes but is not limited to starch, methyl cellulose, agar, bentonite, xanthan gum, etc.
For a composition formulated into a liquid solution, one or more of saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol and ethanol may be added as an acceptable pharmaceutical carrier suitable for sterilization and biological use and, if necessary, another common additive such as an antioxidant, a buffer, a bacteriostat, etc. may be added. In addition, an injectable formulation such as an aqueous solution, a suspension, an emulsion, etc., a pill, a capsule, a granule or a tablet may be formulated by additionally adding a diluent, a dispersant, a surfactant, a binder or a lubricant.
The pharmaceutical composition of the present disclosure may be administered orally or parenterally. The parenteral administration may be accomplished by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal injection, etc. Specifically, it may be administered orally.
The adequate administration dosage of the pharmaceutical composition of the present disclosure varies depending on various factors such as formulation method, administration method, the age, body weight, sex, pathological condition and diet of a patient, administration time, administration route, excretion rate and response sensitivity. An ordinarily skilled physician can easily determine and prescribe an administration dosage effective for the desired treatment or prevention. According to a specific exemplary embodiment of the present disclosure, a daily administration dosage of the pharmaceutical composition of the present disclosure is 0.001-10 g/kg.
The pharmaceutical composition of the present disclosure may be prepared into a single-dose or multiple-dose formulation using a pharmaceutically acceptable carrier and/or excipient. The formulation may be in the form of a solution in an oily or aqueous medium, a suspension, an emulsion, an extract, a powder, a granule, a tablet or a capsule, and may further contain a dispersant or a stabilizer.
In addition, the present disclosure provides a use of the compound represented by Structural Formula 1 or 2 or a pharmaceutically acceptable salt thereof for preparation of a drug for treating a central nervous system disease.
In addition, the present disclosure relates to a method for treating a central nervous system disease, which includes administering the compound represented by Structural Formula 1 or 2 or a pharmaceutically acceptable salt thereof to a mammal.
After dissolving 3-bromobenzaldehyde (1.0 mmol), phenylboronic acid (1.2 mmol), PdCl2 (PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol) in tetrahydrofuran (10 mL) in a reaction vessel, the reaction mixture was refluxed for 24 hours while heating at 70° C. After cooling to room temperature and adding distilled water, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure and the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=20:1) to obtain the target compound (yield: 91%).
1H NMR (400 MHz, CDCl3) δ 10.12; (s, 1H), 8.13; (t, J=1.8 Hz, 1H), 7.89; (dd, J=7.7, 1.8 Hz, 2H), 7.68-7.61; (m, 3H), 7.54-7.48; (m, 2H), 7.46-7.41; (m, 1H).
13C NMR (100 MHz, CDCl3) δ 192.35, 142.19, 139.72, 136.95, 133.08, 129.52, 129.03, 128.65, 128.22, 128.04, 127.17.
After adding the [1,1′-biphenyl]-3-carbaldehyde prepared in the step 1 (1.0 mmol) and pyrrolidine (2.0 mmol) in a reaction vessel and then dissolving with methanol, acetic acid (1.0 mmol) was added and the reaction mixture was stirred at room temperature for 2 hours. After adding sodium triacetoxyborohydride (3.0 mmol), the reaction mixture was stirred for 24 hours. After adding a saturated sodium bicarbonate solution to the reaction mixture and extracting with dichloromethane, the obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=3:1) to obtain compound 1 (yield: 36%).
1 H NMR (400 MHz, CDCl3) δ 7.67-7.61; (m, 2H), 7.61-7.58; (m, 1H), 7.53-7.49; (m, 1H), 7.49-7.39; (m, 3H), 7.39-7.32; (m, 2H), 3.72; (s, 2H), 2.61-2.51; (m, 4H), 1.85-1.79; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 141.50, 140.80, 136.50, 128.99, 128.78, 128.47, 128.43, 127.42, 127.20, 126.65, 59.54, 53.30, 23.28.
Compound 2 (yield: 86%) was obtained using the compound 2′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 85%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 2-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.42-7.31; (m, 2H), 7.34-7.27; (m, 2H), 7.30-7.23; (m, 2H), 7.21; (dd, J=7.1, 1.9 Hz, 2H), 3.62; (s, 2H), 2.52-2.46; (m, 4H), 1.77-1.69; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.59, 139.32, 139.17, 132.55, 131.45, 130.00, 129.91, 128.45, 128.20, 127.98, 127.94, 126.76, 60.63, 54.19, 23.50.
Compound 3 (yield: 85%) was obtained using the compound 3′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 86%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 3-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.63; (t, J=1.9 Hz, 1H), 7.57; (t, J=1.8 Hz, 1H), 7.51; (dt, J=7.5, 1.6 Hz, 1H), 7.48; (dt, J=7.5, 1.7 Hz, 1H), 7.44-7.35; (m, 3H), 7.35-7.31; (m, 1H), 3.71; (s, 2H), 2.60-2.54; (m, 4H), 1.87-1.80; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 143.11, 140.19, 139.77, 134.60, 129.93, 128.80, 128.48, 127.60, 127.35, 127.21, 125.69, 125.39, 60.74, 54.26, 23.51.
Compound 4 (yield: 77%) was obtained using the compound 4′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 78%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 4-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.59-7.53; (m, 3H), 7.47; (dt, J=7.6, 1.7 Hz, 1H), 7.45-7.39; (m, 3H), 7.36; (dt, J=7.4, 1.7 Hz, 1H), 3.71; (s, 2H), 2.62-2.53; (m, 4H), 1.87-1.79; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.12, 139.95, 139.69, 133.30, 128.84, 128.78, 128.47, 128.20, 127.49, 125.57, 60.74, 54.25, 23.50.
Compound 5 (yield: 68%) was obtained using the compound 2′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 93%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 2-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.43-7.32; (m, 2H), 7.36-7.25; (m, 4H), 7.29-7.21; (m, 2H), 3.70; (s, 2H), 2.62-2.50; (m, 4H), 2.31; (s, 3H), 1.89-1.75; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 141.98, 141.84, 139.17, 135.35, 130.26, 129.83, 129.77, 127.96, 127.73, 127.40, 127.18, 125.70, 60.72, 54.19, 23.49, 20.53.
Compound 6 (yield: 83%) was obtained using the compound 3′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 95%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 3-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.59; (t, J=1.9 Hz, 1H), 7.54-7.49; (dt, J=7.5, 1.7 Hz, 1H), 7.47-7.39; (m, 3H), 7.38-7.33; (m, 2H), 7.19; (d, J=7.5 Hz, 1H), 3.74; (s, 2H), 2.64-2.67; (m, 4H), 2.45; (s, 3H), 1.89-1.80; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 141.32, 141.19, 138.28, 128.65, 128.62, 128.03, 127.98, 127.91, 127.81, 125.86, 124.35, 60.72, 54.16, 23.46, 21.56.
Compound 7 (yield: 52%) was obtained using the compound 4′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 96%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 4-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.59; (t, J=1.8 Hz, 1H), 7.57-7.52; (m, 2H), 7.50; (dt, J=7.6, 1.6 Hz, 1H), 7.40; (t, J=7.6 Hz, 1H), 7.34; (dt, J=7.6, 1.6 Hz, 1H), 7.27; (d, J=8.2 Hz, 2H), 3.73 (s, 2H), 2.63-2.56; (m, 4H), 2.43; (s, 3H), 1.89-1.79; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 141.11, 139.67, 138.36, 136.95, 129.42, 128.63, 15 127.65, 127.56, 127.07, 125.59, 60.76, 54.18, 23.50, 21.11.
Compound 8 (yield: 90%) was obtained using the compound 2′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 92%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 2-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.52; (t, J=1.8 Hz, 1H), 7.49-7.44; (dt, J=7.3, 1.7 Hz, 1H), 7.42-7.31; (m, 4H), 7.08-7.02; (td, J=7.5, 1.1 Hz, 1H), 7.02-6.98; (dd, J=8.2, 1.1 Hz, 1H), 3.83; (s, 3H), 3.75; (s, 2H), 2.71-2.55; (m, 4H), 1.90-1.80; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 156.49, 138.46, 138.25, 130.96, 130.67, 130.24, 128.59, 128.30, 127.93, 127.68, 120.82, 111.24, 60.56, 55.58, 54.02, 23.46.
Compound 9 (yield: 78%) was obtained using the compound 3′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 96%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 3-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.48; (t, J=1.7 Hz, 1H), 7.42-7.37 (dt, J=7.5, 1.7 Hz, 1H), 7.33-7.22; (m, 3H), 7.14-7.09; (dt, J=7.7, 1.3 Hz, 1H), 7.08-7.04; (m, 1H), 6.84-6.78; (ddd, J=8.2, 2.6, 0.9 Hz, 1H), 3.78; (s, 3H), 3.61; (s, 2H), 2.48; (m, 4H), 1.76-1.68; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 159.93, 142.79, 141.06, 139.74, 129.69, 128.66, 128.09, 127.78, 125.84, 119.80, 112.99, 112.65, 60.74, 55.35, 54.21, 23.50.
Compound 10 (yield: 95%) was obtained using the compound 4′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 91%) prepared in the same manner as in Example 1 using 3-bromobenzaldehyde (1.0 mmol), 4-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.61-7.55; (m, 3H), 7.50-7.45; (m, 1H), 7.40; (t, J=7.5 Hz, 1H), 7.34-7.29; (m, 1H), 7.03-6.98; (m, 2H), 3.88; (s, 3H), 3.72; (s, 2H), 2.63-2.56; (m, 4H), 1.88-1.80; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 159.13, 140.78, 139.64, 133.77, 128.65, 128.24, 127.35, 127.32, 125.37, 114.15, 60.80, 55.36, 54.22, 23.50.
1H NMR (400 MHz, CDCl3) δ 7.38-7.33; (m, 1H), 7.31-7.27; (m, 2H), 7.27-7.22; (m, 2H), 6.64; (d, J=8.4 Hz, 2H), 3.71; (s, 6H), 3.70; (s, 2H), 2.61-2.56; (m, 4H), 1.82-1.77; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 157.70, 137.63, 133.93, 131.80, 129.61, 128.59, 127.60, 127.55, 119.59, 104.31, 60.49, 55.93, 53.88, 23.47.
After dissolving iodine (0.44 mmol) and sodium iodate (0.22 mmol) in sulfuric acid (10 mL) in a reaction vessel, the reaction mixture was stirred for 30 minutes. After adding 4-chlorobenzaldehyde, the reaction mixture was stirred at room temperature for 2 hours. After cooling to 0° C. and adding distilled water to the reaction mixture, the produced solid was filtered. The filtered solid was added to a sodium thiosulfate solution and extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=10:1) to obtain the target compound (yield: 73%).
1H NMR (400 MHz, CDCl3) δ 9.85; (s, 1H), 8.28; (d, J=1.9 Hz, 1H), 7.73; (dd, J=8.2, 1.9 Hz, 1H), 7.55; (d, J=8.2 Hz, 1H).
13C NMR (100 MHz, CDCl3) δ 189.41, 145.07, 141.38, 135.70, 130.01, 129.96, 98.84.
After dissolving 4-chloro-3-iodobenzaldehyde (1.0 mmol), phenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol) in tetrahydrofuran (10 mL) in a reaction vessel, the reaction mixture was refluxed by heating at 70° C. for 24 hours. After cooling to room temperature and adding distilled water, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=20:1) to obtain the target compound (yield: 96%).
1H NMR (400 MHz, CDCl3) δ 10.05; (s, 1H), 7.88; (s, 1H), 7.83; (d, J=8.0 Hz, 1H), 7.68; (d, J=8.1 Hz, 1H), 7.55-7.43; (m, 5H).
13C NMR (100 MHz, CDCl3) δ 190.96, 141.56, 139.21, 138.09, 135.02, 132.62, 130.90, 129.33, 129.05, 128.32, 128.27.
After dissolving 6-chloro-[1,1′-biphenyl]-3-carbaldehyde (1.0 mmol) and pyrrolidine (2.0 mmol) in methanol in a reaction vessel, acetic acid (1.0 mmol) was added and the reaction mixture was stirred at room temperature for 2 hours. After adding sodium triacetoxyborohydride (3.0 mmol), the reaction mixture was stirred for 24 hours. After adding a saturated sodium bicarbonate solution, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=3:1) to obtain compound 12 (yield: 44%).
1H NMR (400 MHz, CDCl3) δ 7.51-7.38; (m, 6H), 7.35; (d, J=2.2 Hz, 1H), 7.29; (dd, J=8.0, 2.4 Hz, 1H), 3.65; (s, 2H), 2.60-2.51; (m, 4H), 1.86-1.78; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.19, 139.48, 138.37, 131.75, 130.78, 129.73, 129.52, 128.96, 127.99, 127.54, 59.93, 54.19, 23.50.
Compound 13 (yield: 58%) was obtained using the compound 2′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 87%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.49-7.45; (m, 1H), 7.41; (d, J=8.2 Hz, 1H), 7.34-7.27; (m, 4H), 7.25; (d, J=2.1 Hz, 1H), 3.62; (s, 2H), 2.55-2.49; (m, 4H), 1.79; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 138.43, 138.09, 138.01, 133.55, 131.73, 131.52, 131.29, 129.64, 129.41, 129.18, 129.15, 126.44, 59.85, 54.14, 23.51.
Compound 14 (yield: 60%) was obtained using the compound 3′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 85%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.45-7.42; (m, 1H), 7.40; (d, J=7.9 Hz, 1H), 7.36-7.31; (m, 3H), 7.30-7.25; (m, 2H), 3.61; (s, 2H), 2.55-2.47; (m, 4H), 1.83-1.75; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 141.16, 138.82, 138.64, 133.86, 131.49, 130.64, 129.82, 129.59, 129.42, 129.22, 127.81, 127.66, 59.88, 54.21, 23.51.
Compound 15 (yield: 42%) was obtained using the compound 4′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 77%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.41-7.37; (m, 5H), 7.29-7.24; (m, 2H), 3.61; (s, 2H), 2.55-2.48; (m, 4H), 1.82-1.75; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 139.00, 138.62, 137.84, 133.64, 131.49, 130.88, 130.67, 129.82, 129.26, 128.22, 59.89, 54.21, 23.51.
Compound 16 (yield: 62%) was obtained using the compound 6-chloro-2′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 97%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.43; (d, J=8.2 Hz, 1H), 7.37-7.29; (m, 1H), 7.33-7.22; (m, 3H), 7.23; (d, J=2.2 Hz, 1H), 7.18; (dd, J=7.4, 1.4 Hz, 1H), 3.65; (s, 2H), 2.60-2.50; (m, 4H), 2.15; (s, 3H), 1.82; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.27, 139.44, 137.99, 136.24, 131.71, 131.40, 129.76, 129.45, 129.15, 129.04, 127.85, 125.46, 59.88, 54.13, 23.49, 19.84.
Compound 17 (yield: 60%) was obtained using the compound 6-chloro-3′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 97%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.32; (d, J=8.1 Hz, 1H), 7.24-7.15; (m, 5H), 7.11; (d, J=7.2 Hz, 1H), 3.54; (s, 2H), 2.44; (m, 4H), 2.33; (s, 3H), 1.76-1.68; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.32, 139.41, 138.20, 137.61, 131.75, 130.79, 130.17, 129.68, 128.88, 128.29, 127.85, 126.60, 59.93, 54.17, 23.49, 21.49.
Compound 18 (yield: 68%) was obtained using the compound 6-chloro-4′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 64%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.43; (d, J=8.1 Hz, 1H), 7.39; (d, J=7.8 Hz, 2H), 7.33; (d, J=2.1 Hz, 1H), 7.29-7.25; (m, 3H), 3.65; (s, 2H), 2.55; (m, 4H), 2.44; (s, 3H), 1.87-1.76; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 140.15, 138.20, 137.31, 136.57, 131.78, 130.85, 129.71, 129.38, 128.78, 128.72, 59.90, 54.15, 23.49, 21.27.
Compound 19 (yield: 72%) was obtained using the compound 6-chloro-2′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 55%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4(0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.41-7.33; (m, 2H), 7.28-7.22; (m, 2H), 7.22-7.17; (dd, J=7.5, 1.8 Hz, 1H), 7.03-6.98; (td, J=7.5, 1.1 Hz, 1H), 6.98-6.94; (dd, J=7.2, 1.2 Hz, 1H), 3.77; (s, 3H), 3.61; (s, 2H), 2.56-2.46; (m, 4H), 1.83-1.74; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 156.80, 137.78, 137.40, 132.23, 132.09, 131.10, 129.30, 129.07, 128.97, 128.67, 120.32, 111.01, 59.94, 55.64, 54.16, 23.51.
Example 20: Preparation of 1-((6-chloro-3′methoxy-[1,1′-biphenyl]-3-yl)methyl)pyrrolidine
Compound 20 (yield: 86%) was obtained using the compound 6-chloro-3′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 45%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4(0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.45; (d, J=8.1 Hz, 1H), 7.40-7.35; (m, 2H), 7.33-7.29; (dd, J=8.2, 2.2 Hz, 1H), 7.10-7.06; (dt, J=7.6, 1.2 Hz, 1H), 7.05; (t, J=2.1 Hz, 1H), 6.99-6.93; (dd, J=8.2, 2.2 Hz, 1H), 3.87; (s, 3H), 3.66; (s, 2H), 2.56; (m, 4H), 1.83; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 159.20, 140.80, 140.07, 138.19, 131.69, 130.80, 129.77, 129.05, 129.02, 121.99, 115.24, 113.15, 59.87, 55.33, 54.18, 23.51.
Compound 21 (yield: 84%) was obtained using the compound 6-chloro-4′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 55%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4(0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.45-7.39; (m, 3H), 7.33; (d, J=2.2 Hz, 1H), 7.28-7.24; (dd, J=8.1, 2.2 Hz, 1H), 7.01-6.97; (m, 2H), 3.88; (s, 3H), 3.64; (s, 2H), 2.59-2.52; (m, 4H), 1.85-1.79; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 159.08, 139.81, 138.18, 131.86, 131.77, 130.92, 130.68, 129.73, 128.65, 113.43, 59.92, 55.30, 54.17, 23.49.
Compound 22 (yield: 70%) was obtained using the compound 6-chloro-2′,6′-dimethoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 92%) prepared in the same manner as in Example 12 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2,6-dimethoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), pyrrolidine (2.0 mmol), acetic acid (1.0 mmol) and sodium triacetoxyborohydride (3.0 mmol).
1H NMR (400 MHz, CDCl3) δ 7.40; (d, J=8.1 Hz, 1H), 7.31; (t, J=8.3 Hz, 1H), 7.24; (dd, J=8.2, 2.1 Hz, 1H), 7.20; (d, J=2.2 Hz, 1H), 6.64; (d, J=8.4 Hz, 2H), 3.72; (s, 6H), 3.62; (s, 2H), 2.56-2.50; (m, 4H), 1.81-1.75; (m, 4H).
13C NMR (100 MHz, CDCl3) δ 157.85, 137.14, 133.43, 133.02, 133.00, 129.39, 128.93, 128.89, 117.17, 104.11, 59.88, 55.99, 53.98, 23.49.
After dissolving 3-bromobenzaldehyde (1.0 mmol), phenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol) in tetrahydrofuran (10 mL) in a reaction vessel, the reaction mixture was refluxed by heating at 70° C. for 24 hours. After cooling to room temperature and adding distilled water, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (hexane:ethyl acetate=20:1) to obtain the target compound (yield: 91%).
1H NMR (400 MHz, CDCl3) δ 10.12; (s, 1H), 8.13; (t, J=1.8 Hz, 1H), 7.89; (dd, J=7.7, 1.8 Hz, 2H), 7.68-7.61; (m, 3H), 7.54-7.48; (m, 2H), 7.46-7.41; (m, 1H).
13C NMR (100 MHz, CDCl3) δ 192.35, 142.19, 139.72, 136.95, 133.08, 129.52, 129.03, 128.65, 128.22, 128.04, 127.17.
After dissolving the [1,1′-biphenyl]-3-carbaldehyde prepared in the step 1 (1.0 mmol) and ethylenediamine (1.2 mmol) in dichloromethane in a reaction vessel, the reaction mixture was stirred at 0 ° C. for 1 hour. After adding N-bromosuccinimide (1.2 mmol) at the same temperature, the reaction mixture was stirred for 24 hours. After adding a saturated sodium bicarbonate solution, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (dichloromethane:methanol=20:1) to obtain compound 23 (yield: 53%).
1H NMR (400 MHz, DMSO-d6) δ 8.12; (t, J=1.8 Hz, 1H), 7.87-7.82; (dt, J=7.7, 1.4 Hz, 1H), 7.78-7.74; (dt, J=7.8, 1.5 Hz, 1H), 7.74-7.69; (m, 2H), 7.56-7.46; (m, 3H), 7.44-7.36; (m, 1H), 3.64; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.99, 140.54, 140.16, 131.73, 129.46, 129.33, 128.86, 128.17, 127.22, 126.64, 125.81, 50.12.
Compound 24 (yield: 90%) was obtained using the compound 2′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 85%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 2-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.91-7.86; (m, 2H), 7.61-7.57; (m, 1H), 7.57-7.52; (m, 2H), 7.47-7.42; (m, 3H), 3.64; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.88, 139.75, 139.14, 131.97, 131.78, 131.68, 130.62, 130.33, 129.93, 128.68, 128.46, 128.05, 126.99, 49.81.
Compound 25 (yield: 65%) was obtained using the compound 3′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 86%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 3-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 8.17; (t, J=1.8 Hz, 1H), 7.95-7.90; (m, 1H), 7.84; (dt, J=8.0, 1.4 Hz, 1H), 7.81; (t, J=1.9 Hz, 1H), 7.71; (dt, J=7.6, 1.4 Hz, 1H), 7.54; (dt, J=16.0, 7.8 Hz, 2H), 7.46; (dt, J=8.2, 1.4 Hz, 1H), 3.71; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 164.03, 142.03, 139.07, 134.32, 131.30, 130.42, 129.63, 129.62, 128.11, 127.50, 126.97, 126.15, 125.94, 49.24.
Compound 26 (yield: 58%) was obtained using the compound 4′-chloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 78%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 4-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 8.11; (t, J=1.8 Hz, 1H), 7.88-7.84; (dt, J=7.7, 1.4 Hz, 1H), 7.79-7.73; (m, 3H), 7.58-7.51; (m, 3H), 3.65; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.89, 139.19, 138.91, 133.10, 131.62, 129.47, 129.43, 128.98, 128.88, 127.00, 125.74, 50.01.
Compound 27 (yield: 27%) was obtained using the compound 2′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 93%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 2-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.89-7.84; (dt, J=7.7, 1.6 Hz, 1H), 7.82-7.79; (t, J=1.7 Hz, 1H), 7.54-7.47; (t, J=7.6 Hz, 1H), 7.47-7.42; (dt, J=7.6, 1.5 Hz, 1H), 7.33-7.21; (m, 4H), 3.64; (s, 4H), 2.23; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 164.04, 141.69, 141.20, 135.19, 131.42, 130.83, 130.54, 129.97, 128.66, 128.14, 128.03, 126.46, 126.26, 49.77, 20.58.
Compound 28 (yield: 54%) was obtained using the compound 3′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 95%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 3-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) ≢7 8.10; (t, J=1.8 Hz, 1H), 7.85-7.81; (dt, J=7.8, 1.4 Hz, 1H), 7.77-7.72; (dt, J=7.9, 1.4 Hz, 1H), 7.55-7.47; (m, 3H), 7.38; (t, J=7.6 Hz, 1H), 7.21; (d, J=7.5 Hz, 1H), 3.64; (s, 4H), 2.40; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 163.99, 140.62, 140.11, 138.62, 131.68, 129.35, 129.27, 128.83, 128.80, 127.85, 126.54, 125.77, 124.33, 50.21, 21.58.
Compound 29 (yield: 47%) was obtained using the compound 4′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 96%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 4-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 8.12-8.09; (t, J=1.8 Hz, 1H), 7.84-7.79; (dt, J=7.8, 1.4 Hz, 1H), 7.78-7.73; (dt, J=8.0, 1.4 Hz, 1H), 7.65-7.59; (m, 2H), 7.51; (t, J=7.7 Hz, 1H), 7.33-7.28; (m, 2H), 3.66; (s, 4H), 2.36; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 164.11, 140.47, 137.57, 137.14, 131.12, 130.06, 129.35, 128.85, 127.03, 126.40, 125.60, 49.75, 21.15.
Compound 30 (yield: 82%) was obtained using the compound 2′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 92%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 2-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.91; (t, J=1.8 Hz, 1H), 7.80-7.76 (dt, J=7.7, 1.4 Hz, 1H), 7.59-7.54; (dt, J=7.7, 1.4 Hz, 1H), 7.48-7.42; (t, J=7.7 Hz, 1H), 7.41-7.35; (ddd, J=8.2, 7.3, 1.8 Hz, 1H), 7.34-7.30; (dd, J=7.5, 1.8 Hz, 1H), 7.16-7.11; (dd, J=8.3, 1.1 Hz, 1H), 7.08-7.03; (td, J=7.4, 1.1 Hz, 1H), 3.77; (s, 3H), 3.62; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 164.14, 156.58, 138.57, 131.56, 130.93, 130.90, 129.80, 129.60, 128.43, 128.29, 126.05, 121.25, 112.21, 55.99, 50.05.
Compound 31 (yield: 73%) was obtained using the compound 3′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 96%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 3-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3(4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 8.08; (t, J=1.7 Hz, 1H), 7.88-7.82; (dt, J=7.7, 1.3 Hz, 1H), 7.79-7.74; (ddd, J=7.8, 1.9, 1.1 Hz, 1H), 7.51; (t, J=7.7 Hz, 1H), 7.41; (t, J=7.9 Hz, 1H), 7.31-7.25; (ddd, J=7.7, 1.7, 0.9 Hz, 1H), 7.25-7.23; (m, 1H), 7.00-6.95; (ddd, J=8.2, 2.6, 0.9 Hz, 1H), 3.84; (s, 3H), 3.64; (s, 4H).
13H NMR (100 MHz, DMSO-d6) δ 163.94, 160.27, 141.66, 140.42, 131.67, 130.53, 129.28, 128.98, 126.79, 125.83, 119.55, 113.73, 112.75, 55.64, 50.07.
Compound 32 (yield: 60%) was obtained using the compound 4′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 91%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 4-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 8.07; (t, J=1.8 Hz, 1H), 7.82-7.77; (dt, J=7.7, 1.4 Hz, 1H), 7.74-7.69; (dt, J=7.9, 1.4 Hz, 1H), 7.69-7.63; (m, 2H), 7.48; (t, J=7.7 Hz, 1H), 7.08-7.02; (m, 2H), 3.81; (s, 3H), 3.64; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 164.08, 159.56, 140.17, 132.46, 131.64, 129.24, 128.33, 128.30, 125.93, 125.27, 114.88, 55.65, 50.06.
Compound 33 (yield: 55%) was obtained using the compound 2′,6′-dimethoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 89%) prepared in the same manner as in Example 23 using 3-bromobenzaldehyde (1.0 mmol), 2,6-dimethoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.78-7.74; (dt, J=7.8, 1.5 Hz, 1H), 7.68; (t, J=1.7 Hz, 1H), 7.42; (t, J=7.7 Hz, 1H), 7.36-7.28; (m, 2H), 6.76; (d, J=8.4 Hz, 2H), 3.66; (s, 6H), 3.62; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 164.31, 157.61, 134.76, 133.36, 130.02, 129.98, 129.70, 128.00, 125.87, 118.56, 104.81, 56.16, 49.71.
The target compound was synthesized in the same manner as in the step 1 of Example 12.
The target compound was synthesized in the same manner as in the step 2 of Example 12.
After dissolving 6-chloro-[1,1′-biphenyl]-3-carbaldehyde (1.0 mmol) and ethylenediamine (1.2 mmol) in dichloromethane in a reaction vessel, the reaction mixture was stirred at 0° C. for 1 hour. After adding N-bromosuccinimide (1.2 mmol) at the same temperature, the reaction mixture was stirred for 24 hours. After adding a saturated sodium bicarbonate solution, the reaction mixture was extracted with dichloromethane. The obtained organic layer was dried with anhydrous magnesium sulfate and then filtered. After concentrating the filtrate under reduced pressure, the obtained concentrate was separated by column chromatography (dichloromethane:methanol=20:1) to obtain compound 34 (yield: 34%).
1 H NMR (400 MHz, DMSO-d6) δ 7.88-7.84; (m, 2H), 7.67-7.63; (m, 1H), 7.53-7.43; (m, 5H), 3.64; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.01, 140.09, 138.73, 133.68, 130.49, 130.33, 129.87, 129.69, 128.77, 128.47, 128.17, 49.92.
Compound 35 (yield: 50%) was obtained using the compound 2′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 87%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.92; (dd, J=8.4, 2.2 Hz, 1H), 7.79; (d, J=2.1 Hz, 1H), 7.67; (d, J=8.4 Hz, 1H), 7.64-7.58; (m, 1H), 7.51-7.44; (m, 2H), 7.41-7.36; (m, 1H), 3.63; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 162.84, 138.08, 137.74, 134.85, 132.82, 131.73, 130.60, 130.26, 129.78, 129.76, 129.61, 128.92, 127.78, 49.93.
Compound 36 (yield: 49%) was obtained using the compound 3′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 85%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.93-7.89; (m, 2H), 7.73-7.68; (m, 1H), 7.58-7.51; (m, 3H), 7.49-7.44; (m, 1H), 3.70; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.10, 140.49, 138.74, 134.29, 133.46, 130.69, 130.68, 130.61, 129.45, 128.87, 128.68, 128.58, 128.57, 49.13.
Compound 37 (yield: 43%) was obtained using the compound 4′,6-dichloro-[1,1′-biphenyl]-3-carbaldehyde (yield: 77%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-chlorophenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.89-7.86; (m, 2H), 7.67-7.64; (m, 1H), 7.58-7.54; (m, 2H), 7.52-7.48; (m, 2H), 3.64; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 162.96, 138.84, 137.46, 133.71, 133.44, 131.59, 130.42, 129.82, 128.81, 128.52, 49.83.
Compound 38 (yield: 57%) was obtained using the compound 6-chloro-2′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 97%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.89; (dd, J=8.4, 2.2 Hz, 1H), 7.74; (d, J=2.2 Hz, 1H), 7.66; (d, J=8.4 Hz, 1H), 7.36-7.32; (m, 2H), 7.32-7.26; (m, 1H), 7.17-7.12; (m, 1H), 3.65; (s, 4H), 2.06; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 163.07, 140.29, 138.76, 135.93, 134.95, 130.34, 130.21, 129.82, 129.64, 129.10, 128.71, 128.39, 126.28, 49.59, 19.84.
Compound 39 (yield: 47%) was obtained using the compound 6-chloro-3′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 76%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.87-7.81; (m, 2H), 7.66-7.61; (m, 1H), 7.38; (td, J=7.3, 1.1 Hz, 1H), 7.29-7.22; (m, 3H), 3.65; (s, 4H), 2.38; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 163.08, 140.24, 138.66, 138.02, 133.82, 130.51, 130.33, 130.21, 129.56, 129.08, 128.62, 128.11, 126.80, 49.75, 21.46.
Compound 40 (yield: 76%) was obtained using the compound 6-chloro-4′-methyl-[1,1′-biphenyl]-3-carbaldehyde (yield: 64%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-methylphenylboronic acid (1.2 mmol), PdCl2(PPh3)2 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.89-7.82; (m, 2H), 7.67-7.61; (m, 1H), 7.36; (d, J=7.8 Hz, 2H), 7.29; (d, J=7.9 Hz, 2H), 3.66; (s, 4H), 2.37; (s, 3H).
13C NMR (100 MHz, DMSO-d6) δ 163.17, 140.11, 137.87, 135.75, 134.03, 130.57, 130.37, 129.57, 129.32, 128.04, 49.58, 21.26.
Compound 41 (yield: 96%) was obtained using the compound 6-chloro-2′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 55%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.85-7.81; (dd, J=8.3, 2.2 Hz, 1H), 7.75; (d, J=2.1 Hz, 1H), 7.58; (d, J=8.3 Hz, 1H), 7.43; (ddd, J=8.2, 7.4, 1.8 Hz, 1H), 7.20-7.16; (dd, J=7.4, 1.8 Hz, 1H), 7.15-7.11; (dd, J=8.4, 1.0 Hz, 1H), 7.07-7.02; (td, J=7.4, 1.0 Hz, 1H), 3.73; (s, 3H), 3.62; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.09, 156.78, 137.79, 135.38, 130.96, 130.81, 130.30, 129.51, 129.45, 128.02, 127.78, 120.80, 111.83, 55.88, 49.96.
Compound 42 (yield: 37%) was obtained using the compound 6-chloro-3′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 45%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 3-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.88-7.83; (m, 2H), 7.65-7.59; (m, 1H), 7.44-7.37; (m, 1H), 7.05-6.99; (m, 3H), 3.81; (s, 3H), 3.62; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 162.95, 159.50, 140.09, 139.92, 133.51, 130.35, 130.28, 130.13, 129.85, 128.17, 121.99, 115.35, 113.96, 55.65, 50.11.
Compound 43 (yield: 72%) was obtained using the compound 6-chloro-4′-methoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 55%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 4-methoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.87-7.79; (m, 2H), 7.63; (d, J=8.3 Hz, 1H), 7.45-7.38; (m, 2H), 7.08-7.02; (m, 2H), 3.82; (s, 3H), 3.65; (s, 4H).
13C NMR (100 MHz, DMSO-d6) δ 163.16, 159.51, 139.81, 133.99, 130.98, 130.85, 130.54, 130.37, 129.44, 127.80, 114.20, 55.68, 49.66.
Compound 44 (yield: 67%) was obtained using the compound 6-chloro-2′,6′-dimethoxy-[1,1′-biphenyl]-3-carbaldehyde (yield: 92%) prepared in the same manner as in Example 34 using 4-chloro-3-iodobenzaldehyde (1.0 mmol), 2,6-dimethoxyphenylboronic acid (1.2 mmol), Pd(PPh3)4 (0.1 mmol) and Na2CO3 (4.0 mmol), ethylenediamine (1.2 mmol) and N-bromosuccinimide (1.2 mmol).
1H NMR (400 MHz, DMSO-d6) δ 7.99-7.94; (dd, J=8.4, 2.4 Hz, 1H), 7.87-7.81; (m, 2H), 7.43; (t, J=8.4 Hz, 1H), 6.81; (d, J=8.4 Hz, 2H), 3.98; (s, 4H), 3.69; (s, 6H).
13C NMR (100 MHz, DMSO-d6) δ 164.29, 157.57, 140.66, 135.57, 132.84, 131.09, 130.55, 129.11, 121.70, 114.77, 104.69, 56.30, 45.21.
The biphenylpyrrolidine/dihydroimidazole derivatives synthesized in the examples were prepared into various formulations.
5.0 mg of the active ingredient synthesized in each of the examples was sieved, mixed with 14.1 mg of lactose, 0.8 mg of crospovidone USNF and 0.1 mg of magnesium stearate, and then prepared into a tablet by pressing.
5.0 mg of the active ingredient synthesized in each of the examples was sieved, and then mixed with 16.0 mg of lactose and 4.0 mg of starch. Fine granules were prepared by dissolving 0.3 mg of polysorbate 80 in pure water and adding an adequate amount of the solution. After drying, the fine granules were sieved and mixed with 2.7 mg of colloidal silicon dioxide and 2.0 mg of magnesium stearate. A tablet was prepared by compressing the fine granules.
5.0 mg of the active ingredient synthesized in each of the examples was sieved, mixed with 14.8 mg of lactose, 10.0 mg of polyvinylpyrrolidone and 0.2 mg of magnesium stearate and then filled in a hard No. 5 gelatin capsule.
An injection was prepared using 100 mg of the compound synthesized in each of the examples as an active ingredient, 180 mg of mannitol, 26 mg of Na2HPO4·12H2O and 2974 mg of distilled water.
For luminescence-based cAMP assay, HEK293 cells were cultured on a 150-mm dish. Prior to transfection, the culture medium was replaced from DMEM containing 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin to DMEM containing 10% dialyzed FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 4 hours later, transfection was conducted using 10 μg of a human 5-HT7R plasmid and 10 μg of a GloSensor-22F plasmid (Promega). The transfected cells were prepared on a white, flat, clear-bottom, 384-well plate (Greiner) (15,000 cells/well, 20 μL/well). 6 hours later, after removing the culture medium, the cells were treated with 20 μL of a 3% Glosensor cAMP reagent containing luciferin in a 1×HBSS, 1 M HEPES, pH 7.4 buffer. In addition, the compound of each of the examples was prepared at different concentrations in an assay buffer containing 0.1% bovine serum albumin. 30 minutes later, 10 μL of the compound solution was treated to the cells. After measuring luminescence using a Tecan microplate reader (Spark), IC50 value was obtained using the Prism 8.0 program (GraphPad Software).
Table 1 shows the inhibition of the activity of the 5-HT7 serotonin receptor (%) by the biphenylpyrrolidine derivatives of Examples 1-22, and Table 2 shows the inhibition of the activity of the 5-HT7 serotonin receptor (%) by the biphenyldihydroimidazole derivatives of Examples 23-44.
In addition, Table 3 shows the IC50 values of the biphenylpyrrolidine derivatives of the examples, and Table 4 shows the IC50 values of the biphenyldihydroimidazole derivatives of the examples.
Tango assay was conducted using HTLA cells in order to investigate the activity of the β-arrestin signaling system. Prior to transfection, the culture medium was replaced from DMEM containing 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 2 μg/mL puromycin and 100 μg/mL hygromycin B to DMEM containing 10% dialyzed FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 4 hours later, transfection was conducted using 20 μg of a 5-HT7R-TCS-tTA construct (5-HT7R Tango DNA). The transfected cells were prepared on a white, flat, clear-bottom, 384-well plate (Greiner) (15,000 cells/well, 20 μL/well) using DMEM containing 10% dialyzed FBS, 100 U/mL penicillin and 100 μg/mL streptomycin. 6 hours later, after removing the culture medium, the cells were treated with 10 μL of the compound solution. After culturing for 22 hours and removing the culture medium, the cells were treated with 20 μL of a BrightGlo reagent (Promega) diluted in a 1×HBSS, 1 M HEPES, pH 7.4 buffer. After measuring luminescence using a Tecan microplate reader (Spark), IC50 value was obtained using the Prism 8.0 program (GraphPad Software).
Table 5 shows the inhibition of the activity of the 5-HT7 serotonin receptor (%) by the biphenylpyrrolidine derivatives of Examples 1-22, and Table 6 shows the inhibition of the activity of the 5-HT7 serotonin receptor (%) by the biphenyldihydroimidazole derivatives of Examples 23-44.
In addition, Table 7 shows the 1050 values of the biphenylpyrrolidine derivative of Example 1 and the biphenyldihydroimidazole derivatives of the examples.
Schild plots were constructed for the Tango assay in order to investigate the effect of the compounds on the activity of the β-arrestin signaling pathway. After culturing cells and replacing the culture medium as described in b) of Test Example 1, the cells were transfected and prepared on a plate. 6 hours later, the cells were treated with 10 μL of the solution of serotonin or the compounds at final concentrations of 5 μM, 10 μM and 30 μM. After culturing for 22 hours, luminescence was measured using a Tecan microplate reader (Spark) and the Schild plot and the EC50 value were obtained using the Prism 8.0 program (GraphPad Software). In addition, the pA2 value was obtained using the Excel software. The Schild plots and pA2 values of compound 23 and compound 30 according to the present disclosure are summarized in
It can be seen that the biphenylpyrrolidine/dihydroimidazole derivatives according to the present disclosure show antagonistic activity for the 5-HT7 receptor. The Schild plots show that they are competitive inhibitors.
Despite the difference in the structures and physical properties of the substituents, the principles and conditions of the reactions of the examples described above apply to the compounds according to the present disclosure having substituents not described in the examples. Accordingly, it is obvious that those skilled in the art can prepare and investigate the compounds having substituents not described in the examples without special difficulty based on the foregoing disclosure and the common sense in the art.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2020-0165497 | Dec 2020 | KR | national |
This application is a U.S. National Stage Application of International Application No. PCT/KR2021/013410, filed on Sep. 30, 2021, which claims the benefit under 35 USC 119(a) and 365(b) of Korean Patent Application No. 10-2020-0165497, filed on Dec. 1, 2020, in the Korean Intellectual Property Office, the entire disclosures of which are incorporated herein by reference for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2021/013410 | 9/30/2021 | WO |
